Amphastar Pharmaceuticals, Inc. (AMPH)

NASDAQ: AMPH · Delayed Price · USD
24.75
0.12 (0.49%)
At close: Jan 21, 2022 4:00 PM
24.70
-0.05 (-0.20%)
After-hours:Jan 21, 2022 4:12 PM EST
Market Cap1.18B
Revenue (ttm)412.80M
Net Income (ttm)36.08M
Shares Out47.85M
EPS (ttm)0.72
PE Ratio34.28
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume178,352
Open24.37
Previous Close24.63
Day's Range24.22 - 25.33
52-Week Range16.91 - 25.87
Beta0.72
AnalystsBuy
Price Target26.25 (+6.1%)
Earnings DateNov 8, 2021

About AMPH

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone fo...

IndustryPharmaceuticals
IPO DateJun 25, 2014
CEOJack Zhang
Employees1,980
Stock ExchangeNASDAQ
Ticker SymbolAMPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is 26.25, which is an increase of 6.06% from the latest price.

Price Target
$26.25
(6.06% upside)
Analyst Consensus: Buy

News

3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.

Other symbols:RDYTEVA
3 weeks ago - Zacks Investment Research

Amphastar Receives FDA Tentative Approval for Vasopressin

RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's ...

3 weeks ago - Accesswire

Sail Through the Choppy Market With These 3 Low-Beta Stocks

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. Amphastar (AMPH), Sanderson Farms (SAFM) and Sensus Healthcare (SRTS) are well poised to gain.

Other symbols:SAFMSRTS
1 month ago - Zacks Investment Research

3 Stocks With Low PEG Ratios

When screening the market for bargain opportunities, investors may want to look for stocks whose trailing 12-month and forward price-earnings to growth (PEG) ratios are at or below 1.5 as of Dec. 13, wh...

Other symbols:JOUTVIVO
1 month ago - GuruFocus

Why You Shouldn't Bet Against Amphastar Pharmaceuticals (AMPH) Stock

Amphastar Pharmaceuticals (AMPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 month ago - Zacks Investment Research

Bet on These 3 Low-Beta Stocks to Combat Market Volatility

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.

Other symbols:AMNSRTS
1 month ago - Zacks Investment Research

Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communicati...

1 month ago - Accesswire

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communicati...

2 months ago - Accesswire

Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 109.09% and 8.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Amphastar Pharmaceuticals: Q3 Earnings Insights

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

2 months ago - Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021

Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or ...

2 months ago - Accesswire

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8th, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2021 ended September 30, 202...

2 months ago - Accesswire

Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communicati...

4 months ago - Accesswire

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 20...

Other symbols:BHCRDY
5 months ago - Zacks Investment Research

Amphastar Pharmaceuticals (AMPH) Meets Q2 Earnings Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021

Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Co...

5 months ago - Accesswire

Amphastar Pharmaceuticals (AMPH) to Report Q2 Results: Wall Street Expects Earnings Growth

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9th, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2021 ended June 30, 2021, afte...

5 months ago - Accesswire

Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference

RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Commun...

7 months ago - GlobeNewsWire

Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communi...

7 months ago - GlobeNewsWire

Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary

RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuti...

8 months ago - GlobeNewsWire

Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 42.11% and 6.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Recap: Amphastar Pharmaceuticals Q1 Earnings

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.82% over the past year to $0.27, whi...

8 months ago - Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021

Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021

8 months ago - GlobeNewsWire